ERYTECH Provides Business and Financial Update for the Third Quarter of 2022
Conference call and webcast on Tuesday, November 22, 2022 at 8:30am EST / 02:30pm CEST
Conference call and webcast on Tuesday, November 22, 2022 at 8:30am EST / 02:30pm CEST
Erytech announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC regarding its American Depositary Shares ("ADSs")
ERYTECH Pharma today provided a business and financial update for the first half of 2022.
ERYTECH Pharma provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia (ALL) following feedback from the U.S. Food and Drug…
ERYTECH Pharma announced that its Annual General Meeting was held on Friday, June 24, 2022.
ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Hôtel Intercontinental Paris – Le Grand, 2…
ERYTECH Pharma announced that its CEO, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022,…
ERYTECH Pharma provided a business and financial update at the end of March 2022.
ERYTECH Pharma announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the…
ERYTECH Pharma announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies.